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Introduction {#sec1}
============

The stem cell (SC) genome is highly plastic, allowing rapid changes in global gene expression patterns to self-renew and differentiate, adopting different cell fates. In embryonic SCs, genome plasticity is influenced by special epigenetic states, with specific patterns and levels of histone H3 K4me3, K9me3, and K27me3 (H3 K4/9/27me3). In particular, global hypomethylation of histone H3 K9/27me3, two transcriptional repressive marks, regulate embryonic SC plasticity ([@bib7], [@bib8], [@bib14], [@bib20], [@bib34], [@bib39], [@bib40]).

Tissue SC behavior and cell fate acquisition, or "SC dynamics," are critical for tissue regeneration in both normal homeostasis and injury repair, and must be tightly linked with genome plasticity. However, mechanisms of adult tissue SC genome plasticity are poorly understood *in vivo*, due to SC scarcity and inaccessibility to their niche ([@bib2], [@bib4]). Importantly, many tissue SCs (e.g., muscle, blood, and hair follicle) are quiescent before cell fate changes ([@bib10]). Intriguingly, hypomethylation of histone H3 K9/27me3 correlates with quiescence in muscle SCs *in vivo* and T cells *in vitro* ([@bib3], [@bib33]). Furthermore, hypomethylation is required for genome plasticity of quiescent T cells ([@bib3]). Recently, we showed hypomethylation of quiescent hair follicle (HF) SCs of H3 K9/27me3 and also of H3 K4me3 marks ([@bib28]). Hypomethylation occurs at a stage of hair homeostasis (hair cycle) known as Catagen ([@bib22], [@bib28]), which precedes HFSC fate determination occurring at Telogen, when HFSC either locate in their niche (bulge) or in the activation/differentiation zone known as hair germ ([@bib15], [@bib25]). Location determines subsequent cell fate, finalized by Anagen, when cells in the bulge self-renew while the hair germ proliferate and irreversibly differentiate to matrix progenitors and further to hair shaft. Because cell fate is undetermined in Catagen, it follows that cells must likely be characterized by highest genome plasticity ([@bib45]). Similar with embryonic SCs, the catagen hypomethylation of HFSCs might allow high plasticity, or flexibility in subsequent SC fate acquisition ([Figure 1](#fig1){ref-type="fig"}A). In fact, we found that other measurements of plasticity, such as dynamic exchange of chromatin-bound factors, and reprogramming ability by the Yamanaka 4F factors are also elevated at Catagen ([@bib27]).Figure 1Injury Repair Is Delayed after Demethylase Inhibitor Application in Mouse Back Skin during Late Anagen/Catagen(A) Scheme of cellular plasticity and methylation levels in quiescent and activated HFSCs.(B) Scheme of demethylase inhibitor (DI) application and the punch wound experiment. A, Anagen; C, Catagen; T, Telogen; PD, postnatal day.(C) Western blots for control vehicle (CT) or DI applied to wild-type mice during late Anagen/Catagen (PD35-42) phase and sacrificed at the ages indicated at top. For the whole blot, see [Figure S1](#mmc1){ref-type="supplementary-material"}A.(D) Quantification of the western blots in (B and [S1](#mmc1){ref-type="supplementary-material"}A). Three mice were used per time point for statistical analysis. ^∗^p = 0.005, ^∗∗^p = 0.005, ^∗∗∗^p = 0.009.(E) Punch wound pictures of (PD35-42) CT- or DI-treated mice at different days after the punch wound.(F) Punch wound size measurements on images like those in (E). N = 5 mice per group. ANOVA was used for significance test.(G) Tenascin and K10 staining skin sections including the punch wound of wild-type mice after CT or DI application 1 week after the wound. Panels on the left are enlargements of corresponding white dotted line insets on the right.(H) Blood vessel (CD31) and DNA (Hoechst) staining in 1-week punch wound skin sections of wild-type mice after CT or DI application. Arrows indicate the wound edges at the junction with normal skin.(I) Fibroblast (vimentin) and K14 staining in 1-week punch wound skin sections of wild-type mice after CT or DI application. Arrows indicate the wound edges at the junction with normal skin.Student's t test was used for all significance tests except (F). All the experiments were executed twice. Scale bars, 20 μm.

We demonstrated that interfering with hypomethylation at Catagen in adult skin can affect HFSC activation and the onset of hair growth ([@bib28]). It remained unclear whether hypomethylation effect on hair growth is stage specific, and whether it is relevant to hair cycle stages beyond SC activation and to wound healing. To address these questions, here we block H3 K4/9/27me3 hypomethylation by applying histone demethylase inhibitors (DIs) to adult mouse skin at different hair cycle stages. Hypomethylation at late Anagen/Catagen proved relevant for subsequent skin repair of punch wounds, specifically acting on keratinocyte differentiation and recruitment of blood vessels, but not on keratinocyte proliferation or recruitment of fibroblast. We studied hypomethylation effect on behavior of two SC populations located either in the inter-follicular epidermis (IEF) or the HF. We characterize abnormal spindle microtubule assembly (*Aspm*)-CreER mice ([@bib36]) for their induction in the skin and demonstrate robust labeling in the inter-follicular epidermis (IFE), which provides new genetic tools for skin targeting. We use the *Lgr5*-CreER, as a known driver in the HFSC lineage to examine effect of methylation level on HF contribution to wound healing ([@bib19]). We find that interfering with hypomethylation affects migration and contribution to wound healing of both IFE and HF lineages. Hypomethylation was relevant to HFSC activation timing, as reported ([@bib28]), but here we show that HFs eventually grow, albeit with transient defects in differentiation. Hypomethylation interference and subsequent hair growth defects are hair cycle stage dependent and do not occur at anagen; Hypomethylation also affects the levels of BMP4 expression. BMP-signaling controls hair cycle progression, HFSC activation and differentiation ([@bib6], [@bib26]), and also acts in wound healing ([@bib30]). BMP4 elevation in skin correlates with selective increase of activating mark H3 K4me3 (but not of H3 K9/27me3) on the *Bmp4* promoter in response to hypomethylation interference. Thus, hair cycle-specific H3 K4/9/27me3 hypomethylation is relevant for IFE and HFSC function in homeostasis and wound healing, likely in part through BMP signaling. We provide a model and general road map for future genetic studies of histone methylation role in the skin and for clinical investigation.

Results {#sec2}
=======

Impaired Hypomethylation Delays Skin Wound Healing {#sec2.1}
--------------------------------------------------

To examine histone H3 K4/9/27me3 hypomethylation relevance to wound healing, we applied DIs to mouse back skin at late Anagen/Catagen (postnatal day \[PD\]35--42) when hypomethylation is strong ([@bib28]) ([Figure 1](#fig1){ref-type="fig"}B). These DIs have been shown to target specifically the H3 K4 and K9 de-methylases (JIB 04) and K27 demethylases (GSK J1) ([@bib24], [@bib28], [@bib49]), and induced H3 K4/9/27me3 elevation through later stages ([Figures 1](#fig1){ref-type="fig"}C, 1D, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B), as expected. Next, we applied a punch wound at PD49, and measured delayed wound area closure relative to the original wound size ([Figures 1](#fig1){ref-type="fig"}E and 1F). Next, we examined specific cellular processes important in wound healing. Expression of spinous layer differentiation markers keratin 1 and 10 was decreased in the DI-treated wounded skin relative to control while the basal layer (BL) markers K14 and α6-integrin were maintained ([Figures 1](#fig1){ref-type="fig"}G, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D). Proliferation of BL cells, indicated by Ki67 staining, was not affected ([Figure S1](#mmc1){ref-type="supplementary-material"}D). In addition to keratinocytes, blood vessels and fibroblasts from the nearby dermis are also recruited to the wounded site ([@bib37]). Strikingly, vascularization as determined by CD31 staining, was extremely delayed in DI-treated skin wounds ([Figures 1](#fig1){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}E), whereas, fibroblast recruitment determined by vimentin staining was normal ([Figure 1](#fig1){ref-type="fig"}I). Thus, impairing hypomethylation during Catagen delays injury repair along with epidermal differentiation and blood vessel recruitment, but not epidermal proliferation and fibroblast recruitment at the wound site.

*Aspm*-CreER Genetic Tools to Mark the IFE BL SCs {#sec2.2}
-------------------------------------------------

Subsequently, we wanted to examine whether H3 K4/9/27me3 levels may differentially affect contributions to wound healing from SC populations of the HF versus the IFE. For this, we employed genetic lineage tracing tools using tamoxifen (TM) inducible CreER recombinase that marks specifically SCs in the HF via *Lgr5*-CreER ([@bib19]) ([Figure 2](#fig2){ref-type="fig"}A). For the IFE, we tested a potential driver *Aspm*-CreER ([@bib36]) that surfaced as a specific candidate of IFE marker not found in the HF, from our previous microarray analysis ([@bib46]) ([Figure 2](#fig2){ref-type="fig"}A). The differential expression of *Lgr5* and *Aspm* markers in HFSCs and epidermal BL cells was first confirmed by qRT-PCR analysis of fluorescence-activated cell sorting (FACS)-sorted CD34+/α6-integrin+ as HFSCs and CD34−/α6-integrin+ as BL-enriched cells ([Figure 2](#fig2){ref-type="fig"}B).Figure 2Lineage Tracing of Inter-Follicular Epidermis Stem Cells in Aspm-CreER Mice(A) Scheme of the epithelial skin structure with epidermis at the top and HF at the bottom. CL, cornified layer; G/SL, granular/spinous layer; BL, basal layer; SG, sebaceous gland; HFSC, HF stem cell; HG, hair germ; DP, dermal papilla. Note the marking of epidermis versus HF using *Aspm*-CreER versus *Lgr5*-CreER genetic drivers.(B) Gene expression analysis of FACS-sorted inter-follicular epidermis (IFE) BL cells and HFSCs in Catagen (PD41) and Anagen (PD24). N = 3 of biological replicates; ^∗^p = 0.009, ^∗∗^p = 0.0002, ^∗∗∗^p = 0.017, ^∗∗∗∗^p = 0.001. HFSCs are FACS sorted as α6-integrin+/CD34+ and BL cells were α6-integrin+/CD34− cells. Student's t test was used for all significance tests.(C) Scheme of lineage tracing using *Aspm*-CreER;Rosa26-tdTomato mice after tamoxifen (TM) injection (red arrows) and different experimental endpoints (black arrowhead); \'sac\' stands for time of sacrifice.(D) Back skin of *Aspm*-CreER;tdTomato mice treated as shown in (C) at endpoints indicated. Arrowhead shows *Aspm*-CreER-marked cells positive for tdTomato. Asterisk indicates autofluorescence from the hair shaft. N = 2 for TM−; N = 3 for the rest of the time points.(E) Experimental scheme and whole-mouse pictures showing back skin hair plucking of *Aspm*-CreER;tdTomato mice at time points indicated. Note that the right-hand side was plucked, and the hairs grew back by 2 weeks post-plucking. N = 3.(F) Lineage tracing of *Aspm*-CreER-marked positive IFE cells at PD98, 1 month after plucking. Left panel shows no migration in the HFs. Middle panel shows migration of Aspm cells to the infundibulum (arrowhead). Right panel shows migration of Aspm cells to the bulge (arrowhead). N = 3. The table was generated from averaging 100 HFs from 3 mice at 1 month after hair plucking.Scale bars, 20 μm.

To test the *Aspm*-CreER-marked cells for their localization and contribution to skin homeostasis, we used the Rosa26-tdTomato reporter mice ([@bib35]) induced with TM at PD28 ([Figure 2](#fig2){ref-type="fig"}C). We found that at 1 day and 2 weeks after TM injection, abundant tdTomato+ cells were present in the IFE and were excluded from the HFs ([Figure 2](#fig2){ref-type="fig"}D). To ask if the *Aspm*-CreER-marked IFE cells possess long-term SC potential, we lineage traced these cells up to 1 year ([Figure 2](#fig2){ref-type="fig"}C, bottom). By 3 months, tdTomato *Aspm*-CreER-marked progeny survived and proliferated in the BL, and were present in the suprabasal (differentiated) layers ([Figure 2](#fig2){ref-type="fig"}D). By 1 year, they formed frequent large multiple-cell clones in the IFE, with rare marking of the infundibulum (∼6% of HFs) and no marking in the lower HF ([Figures 2](#fig2){ref-type="fig"}D and 2F). To further characterize the potential of *Aspm*-CreER-marked cells, we plucked the back skin hair ([Figure 2](#fig2){ref-type="fig"}E) and found little, if any, contribution to HFs bellow the infundibulum area ([Figures 2](#fig2){ref-type="fig"}E, 2F, and [S2](#mmc1){ref-type="supplementary-material"}). Taken together, these results suggest that *Aspm*-CreER marks specifically and efficiently the IFE and its SCs, away from the HF, and is thus a valuable tool to study long-term behavior of IFE lineages in adult skin without influence from HF phenotypes.

Impaired Hypomethylation Affects IFE SC Contribution to Wound Healing {#sec2.3}
---------------------------------------------------------------------

Next, we asked if *Aspm*-CreER/Rosa26-tdTomato-marked IFE cells contribute to wound healing and if DI affects this contribution ([Figure 3](#fig3){ref-type="fig"}A). We injected TM once at PD28 and applied DIs (PD35-42) on back skin to block hypomethylation. After a week (PD49), we apply a punch wound and examined the tdTomato-marked progeny cells ([Figure 3](#fig3){ref-type="fig"}B). Similar to previous experiments, wound closure was delayed by DIs ([Figures 3](#fig3){ref-type="fig"}C and 3D). Prominent tdTomato trails in the punch wound area, indicated robust contribution of *Aspm*-CreER IFE cells to injury repair in normal but not DI-treated skin ([Figures 3](#fig3){ref-type="fig"}E--3G). Interestingly, *Aspm*-CreER-marked cells contributed substantially to HF regeneration near the injury site, both in CD34+ HFSCs and bulge inner layer ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). This differed from lack of contribution to HFs in the plucking experiment ([Figure 2](#fig2){ref-type="fig"}F). This suggested that punch wounds deliver a strong incentive to the IFE cells to trans-differentiate to HF. This "trans-differentiation" was modestly, if at all affected by our DI treatment ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Taken together, our data demonstrate that IFE SC migration and contribution to wound healing is impaired when hypomethylation of skin is blocked prior to injury.Figure 3Epidermal Stem Cell Contribution to Wounding Is Impaired by Blocking Hypomethylation at Late Anagen/Catagen(A and B) Scheme of the *Aspm*-CreER;tdTomato mouse punch wound (A) with the experimental timeline (B).(C) Pictures of (PD35-42) CT- or DI-treated *Aspm*-CreER;tdTomato mice at different days after the punch wound.(D) Punch wound size measurement in (C). N = 3 mice per group. ANOVA was used for the significance test.(E) Sections of skin containing a punch wound 1 week after wounding. Arrows indicate the wound edge neighboring normal skin. Note the prominent trails of tdTomato+ cells in CT skin.(F) Quantification of the tdTomato signals in the wounded area at 1 week. N = 3; p = 0.0007.(G) Confocal images of the wounded region after 1 week of the wound. White dashed lines indicate the injury site. N = 3.Student's t test was used for the significance test in (F). Scale bars, 20 μm.

Impaired Hypomethylation Affects the HFSC Contribution to Wound Healing {#sec2.4}
-----------------------------------------------------------------------

Next, we asked if *Lgr5*-CreER ([@bib19]), Rosa26-tdTomato-marked HFSC progeny cells contribute to wound healing in our assay, and if DI affects this ([Figures 4](#fig4){ref-type="fig"}A and 4B). In control mice, *Lgr5*-CreER HFSC progeny migrated and differentiated into basal and suprabasal epidermis forming prominent tdTomato+ trails at 1, 3, and 5 weeks post-wound ([Figures 4](#fig4){ref-type="fig"}C--4F). However, in DI-treated skin, tdTomato+ cells from the HF migrated much less, and remained confined to the bulge ([Figures 4](#fig4){ref-type="fig"}C--4F). These data suggest that hypomethylation at late Anagen/Catagen is relevant to subsequent HFSC progeny migration and contribution to epidermis injury repair.Figure 4Hair Follicle Stem Cell Contribution to Wounding Is Impaired by Blocking Hypomethylation at Late Anagen/Catagen(A and B) Scheme of the *Lgr5*-CreER;tdTomato mouse punch wound experiment (A) with the experimental timeline (B).(C) Confocal images of the wounded region 1, 3, and 5 weeks after the punch wound. White dashed lines indicate the injury site. For 1 and 5 weeks, N = 2; for 3 weeks, N = 3.(D) Quantification of the Lgr5 lineage traced signals inside the wound region. ^∗^p = 0.015. Student's t test was used for the significance test.(E) Skin sections 1 week after the punch wound shows *Lgr5*-CreER;tdTomato-marked cells trailing from the HF bulge toward the epidermis.(F) Skin sections of the wounded area 3 weeks after the punch wound. Note prominent tdTomato+ cells present in CT skin, indicating the contribution of HF stem cells to injury and negative effects in DI-treated skin. Scale bars, 20 μm.

Histone H3 K4/9/27me3 Hypomethylation of Skin Is Significant for Subsequent Hair Growth and Differentiation {#sec2.5}
-----------------------------------------------------------------------------------------------------------

Quiescent HFSCs are activated by wounding and enter a new growth phase, and this growth rapidly spreads away from the wound (controls in [Figures 5](#fig5){ref-type="fig"}A and 5B). Blocking hypomethylation with DIs at late Anagen/Catagen (PD35-42), when HFSCs enter quiescence and methylation marks are erased, delayed hair cycle progression up to PD98 ([@bib28]). Here, we examined hair growth in wounds and at time points past PD98, investigate possible effects on differentiation, and ask if DI activity is hair cycle stage dependent.Figure 5Hair Growth Is Delayed and Hair Differentiation Is Impaired by Blocking Hypomethylation at Late Anagen/Catagen, but Not at Anagen(A) Whole view of mice 5 weeks after the punch wound. Note the restricted hair growth in the punch wound area in a DI-treated mouse (right panel) and spreading away from the wound area in a CT mouse (left panel).(B) Skin sections of the wounded area from CT- or DI-treated mice 3 weeks after wounding. Note the Anagen morphology in HFs near the wound edge spreading further into the neighboring regions in CT- but not DI-treated mice.(C) Experimental scheme with DI treatment at Anagen (green arrow) or late Anagen/Catagen (orange arrow) and timeline with the number of mice analyzed for CT- or DI-treated wild-type mice.(D) Representative images of the shaved mouse back skin at different ages after applying CT or DI (PD35-42). Number of mice in each age is indicated in (C).(E) Western blots for CT- or DI-treated mice during Anagen (PD28-35) phase show no differences in methylation levels. In contrast, application at PD35-42 induces prominent differences (1C, 1D, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B).(F) Quantification of the western blots in (E) and additional blots in Figure S4A (N = 3 mice/group).(G) Whole view of mouse back skin at PD98 after applying CT or DI at the time points indicated on the left. Note the normal hair growth in the top panels and delayed hair growth in the bottom right panels.(H and I) Skin sections of CT- or DI-treated mice (PD35-42 induction scheme) at PD98 or PD129 show HFs with distinct morphology (H) and patterns of marker staining (I). The white arrowhead indicates an AE13+/Ki67+ cell.(J) Quantification of the AE13 signal intensity/cell. N = 3; ^∗^p \< 0.0001.(K) Quantification of the Ki67+ cells in AE13+ cells in (I). N = 3; ^∗^p \< 0.0001.Student's t test was used for all significance tests. All experiments were executed twice. Scale bars, 20 μm.

In wounds, hair growth occurred in all mice but its spreading in neighboring regions was delayed by DI treatment ([Figures 5](#fig5){ref-type="fig"}A and 5B). Second, HF growth was arrested at Telogen in DI-treated skin away from wounds, in line with previous report that normal hair growth is delayed by DI ([@bib28]). Eventually, hair shafts appeared fully grown in most back skin regions by ∼PD129 ([Figures 5](#fig5){ref-type="fig"}C and 5D); thus, HF growth impairment induced by blocking hypomethylation at the late Anagen/Catagen is eventually overcome. To investigate if the hair cycle stage at which we inhibit hypomethylation is important for subsequent hair growth, we applied DIs during Anagen (PD28-35), where HFSCs are proliferative ([Figure 5](#fig5){ref-type="fig"}C, green arrow). Interestingly, applying DIs at Anagen (PD28-35) did not affect the skin histone methylation levels nor the hair growth, as seen before with late Anagen/Catagen (PD35-42) applications ([Figures 5](#fig5){ref-type="fig"}C, 5E--5G, and [S4](#mmc1){ref-type="supplementary-material"}A). This suggested a hair cycle stage-dependent activity of histone H3 demethylases, confined to late Anagen/Catagen.

Previously, we showed a delay in proliferation onset in the hair germ in mouse skin treated with DIs at PD35-42 and stained with Ki67 and sacrificed at PD56 ([@bib28]). Here, we show by Ki67 staining that DI-treated skin was at early Anagen at PD98 and at Anagen in PD129, whereas control skin was at full Anagen and Telogen, respectively ([Figure 5](#fig5){ref-type="fig"}H). Interestingly, DI-treated HFs displayed abnormal morphology, with an uncharacteristic narrow bulb ([Figure 5](#fig5){ref-type="fig"}H), not accompanied by detectable apoptosis or DNA damage response ([Figure S4](#mmc1){ref-type="supplementary-material"}B and data not shown), suggesting possible defects in the production of inner differentiated layers. This possibility was supported by decreased AE13 expression ([Figures 5](#fig5){ref-type="fig"}I and 5J). Furthermore, we detected more AE13+ cells that also proliferate (Ki67+), normally a rare occurrence ([Figures 5](#fig5){ref-type="fig"}I and 5K), and outer-root sheet in hair bulb also proliferated more ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). In conclusion, here we demonstrate that interfering with hypomethylation at late Anagen/Catagen delays Anagen onset, followed by an abnormal pattern of differentiation and proliferation at Anagen. The HFs eventually grow mature hair shafts. Importantly, we also demonstrate that DI treatment does not work at Anagen in perturbing methylation levels in HFs, and in affecting hair growth. This effect is specific to late Anagen/Catagen, the stage when HFSCs enter quiescence and hypomethylation is apparent ([@bib28]). This suggests that it is selectively at this stage when demethylases act in skin and HFs.

Histone H3 K4/9/27me3 Levels Act on BMP Signals {#sec2.6}
-----------------------------------------------

Next, we wondered how interfering with histone methylation level at late Anagen/Catagen may result in hair cycle defects and delays in epithelial cell migration and differentiation during injury repair. BMP signaling is known for controlling SC quiescence, hair cycle progression, HF cell differentiation, and migration and differentiation in wound healing ([@bib5], [@bib21], [@bib23], [@bib30], [@bib31], [@bib44], [@bib50]). Thus, an increase in BMP signaling could potentially explain, at least in part, the skin phenotypes induced by blocked hypomethylation at late Anagen/Catagen. BMP4 protein levels and histone methylation levels, were examined in normal skin by western blots at several key hair cycle stages ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). At the onset of HFSC quiescence (late Anagen/Catagen, PD35-39), methylation decreases while BMP4 increases. When HFSC are activated (Telogen/Anagen, PD49-62), a reversed negative correlation occurs, when methylation increases and BMP4 decreases ([Figure 4](#fig4){ref-type="fig"}A). Interestingly, we noticed a positive correlation in the late stages of quiescence (Catagen/Telogen, PD44-49), where both methylation and BMP4 expression increased ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). Significantly, DI-treated skin (e.g., with elevated methylation) showed an increase in BMP4 protein levels by western blots at all stages analyzed ([Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A). The *Bmp4* mRNA was also increased as shown by qRT-PCR of total skin at Catagen ([Figure 6](#fig6){ref-type="fig"}B). Wild-type bulge and non-bulge basal cells, FACS sorted as CD34+/α6-integrin+ and CD34−/α6-integrin+ cells, showed elevated expression of *Bmp4* at Catagen and Telogen relative to Anagen ([Figure S5](#mmc1){ref-type="supplementary-material"}B), suggesting that the epithelial SCs are one source of BMP signals. Staining for BMP4 protein expression showed increased signal both in the CD34+ HFSCs and in the BL epidermis in DI-treated skin ([Figures 6](#fig6){ref-type="fig"}C, 6D, and [S5](#mmc1){ref-type="supplementary-material"}C).Figure 6BMP4 Expression Is Increased by Blocking Hypomethylation at Late Anagen/Catagen(A) Intensity graph of BMP4 normalized by β-actin of CT-treated (blue) or DI-treated (red) mice at late Anagen/Catagen extracted from western blots in [Figure S5](#mmc1){ref-type="supplementary-material"}A at the ages and stages indicated. N = 2 for PD35; N = 3 for other ages. A, Anagen; C, Catagen; T, Telogen. Corresponding histone methylation levels normalized by H3 of CT-treated mice total skin at various ages are shown in gray and were extracted from [@bib28]. Note the decrease in histone methylation level from Anagen to Catagen transition, accompanied by an increase in BMP4 levels. From Catagen to Telogen, histone methylation and BMP4 levels positively correlate, while from Telogen to Anagen, methylation continues to increase while BMP4 levels decrease.(B) Gene expression analysis of *Bmp4* mRNA in CT- or DI-treated total back skin. N = 3 of biological replicates; ^∗^p = 0.018.(C) Skin sections immunostained with BMP4 show expression of BMP4 in bulge and epidermis with apparent increase in DI-treated skin. Bu, bulge; Ep, epidermis.(D) BMP4 fluorescence signal quantification in the bulge (CD34+ cells) and the basal layer cells as shown in Figure S5B. N = 3; ^∗^p = 0.022, ^∗∗^p = 0.003. Bu, bulge; Ep, epidermis.(E) Scheme of the *Bmp4* promoter region with three primer sets upstream of the transcription start site (TSS) used for the P experiment of CT- or DI-treated skin.(F) ChIP signal fold change of *Bmp4* promoter regions 1, 2, and 3 shown in (E). ^∗^p = 0.047, ^∗∗^p = 0.012, ^∗∗∗^p = 0.029, ^∗∗∗∗^p = 0.017, ^∗∗∗∗∗^p = 0.04; N = 2 for Anagen (PD35) samples, N = 3 for Catagen (PD39) samples. The samples that were used for the ChIP experiments were the total skin samples of biological replicates after applying DI or control vehicles (CT).(G) Scheme of the NOGGIN-coated bead injection experiment after applying DI.(H) Skin sections immunostained with CD34 and Ki67 from mice sacrificed at PD53 after injecting NOGGIN in DI-treated skin.(I) Quantification of the HFs in each hair cycle from (H). N = 3; ^∗^p = 0.014.(J) Skin sections immunostained with CD34 and pSMAD1, 5, 9 at PD49 after applying DI at PD35-42.(K) Quantification of fluorescence signals of pSMAD1, 5, 9 in the bulge (CD34+ cells) as shown in (J). N = 3; ^∗^p = 0.004.(L) Working model describing histone methylation level crosstalk with BMP4.Student's t test was used for all significance test. All experiments were executed twice. Scale bars, 20 μm.

To understand how increasing the histone methylation levels may elevate BMP4, we began by analyzing the status of H3 K4/9/27me3 at the *Bmp4* gene locus using our previous chromatin immunoprecipitation (ChIP) sequencing results of sorted bulge HFSCs and non-bulge cells at Anagen and Catagen ([@bib28]). Interestingly, transcription repression marks H3 K9/27me3 were removed from the *Bmp4* gene and promoter in the HFSCs by Catagen, while the transcription activation mark H3 K4me3 was considerably kept ([Figure S5](#mmc1){ref-type="supplementary-material"}D). This was consistent with elevated expression of BMP4 at late quiescence stages in the epithelial cells ([Figure 6](#fig6){ref-type="fig"}A, 5B, and [S5](#mmc1){ref-type="supplementary-material"}B). Next, we performed ChIP analysis of DI-treated skin at Anagen and Catagen to probe the level of H3 K4/9/27me3 marks on three *Bmp4* promoter regions previously shown to be functionally relevant for its expression ([Figure 6](#fig6){ref-type="fig"}E) ([@bib50]). The repressive marks (H3 K27me3 and H3 K9me3) were decreased in control mice at Catagen when compared with Anagen, as expected. However, they did not significantly change on promoter regions 1 and 2 in response to DI treatment. In contrast, promoter region 3 showed an increase in the activating mark H3 K4me3 at Catagen in DI-treated skin ([Figure 6](#fig6){ref-type="fig"}F). These data together suggest that despite global inhibition of H3 K4/9/27me3 demethylases, *Bmp4* promoter regions are selectively demethylated, generally retaining H3 K4me3 and losing the H3 K9/K27me3. This selective pattern is not common throughout the genome, as demonstrated in a control tested gene ([Figure S5](#mmc1){ref-type="supplementary-material"}E). These results could explain the observed increase of *Bmp4* mRNA and protein expression in DI-treated skin with blocked hypomethylation.

To confirm that the BMP signaling is hyperactive after applying DIs, we performed a rescue experiment using NOGGIN, which is a well-known BMP antagonist in skin ([@bib43]). After injecting the recombinant mouse NOGGIN in DI-treated skin, the hair cycle delay phenotype was rescued when compared with control PBS injected skin where follicles were still in Telogen ([Figures 6](#fig6){ref-type="fig"}G--6I and [S5](#mmc1){ref-type="supplementary-material"}F). Furthermore, to investigate if increased BMP4 levels in DI-treated skin affects the BMP signaling, we analyzed the DI-treated skin with phosphorylated SMAD 1/5/9, which is a reporter of canonical BMP signaling ([@bib5]). Indeed, we observed increased pSMAD signal in the CD34+ HFSCs ([Figures 6](#fig6){ref-type="fig"}J and 6K). Normally pSMAD staining disappears when the HFs enter Anagen ([@bib12]). However, pSMAD signal was still maintained in the DI-treated HFs adjacent to the wound ([Figure S5](#mmc1){ref-type="supplementary-material"}G). This coincides with our results that spreading of the hair activation signals from the wound is more restricted in DI-treated skin ([Figure 5](#fig5){ref-type="fig"}B). Together, these data suggest that the canonical BMP pathway is hyperactive after blocking the hypomethylation during the Anagen/Catagen phase, because of selective targeting of the *Bmp4* promoter and increased BMP4 levels in the skin.

Discussion {#sec3}
==========

Here, we demonstrate an impact of global histone H3 K4/9/27me3 levels in SC dynamics and cell fate decision during adult skin regeneration: hair cycle and wound healing. Hypomethylation of histone H3 K4/9/27me3 and HFSC quiescence occur concomitantly at late Anagen/Catagen ([@bib28]). We briefly interfere with the H3 K4/9/27me3 demethylases at this critical stage and identify remarkable long-term physiological effects on SC behavior in both HF and epidermis, along with impaired wound healing and defects in hair growth and differentiation. We show that chemical inhibition of demethylases is dependent on hair cycle stage. Finally, we implicate BMP4 as a downstream effector of hypomethylation that may at least in part explain these physiological effects. Our data provides a broad road map for future genetic studies of the control of H3 K4/9/27me3 levels in skin for proper hair growth and wound healing. We suggest possible pharmaco-chemical strategies to interfere with H3 K4/9/27me3 levels for future clinical studies.

Previously, we hypothesized that H3 K4/9/27me3 hypomethylation of HFSCs at Catagen was important for keeping the SCs in a highly plastic state of low epigenetic identity, such that HFSCs can easily adopt more differentiated cell fates in the subsequent stages of hair cycle ([@bib22], [@bib28]). Our data here support this model, as inhibiting hypomethylation impairs the hair germ fate (this work), which is critical for HFSC activation ([@bib13]), and also impairs proper HF differentiation to inner hair lineages (this work). It is remarkable that one week of DI treatment at a critical hair cycle stage can induce physiological effects in skin 60--80 days post-treatment. In this critical stage histone demethylases must be highly active, explaining the hypomethylation and as demonstrated by the time-selective response to DIs. H3 K4/9/27me3 methylases are also downregulated at this stage relative to Anagen ([@bib28] and this work). Whereas at Catagen HFSC are hypomethylated and highly plastic, at Anagen they are likely in a state of high epigenetic identity, or a "rigid" stem cell fate state that promotes self-renewal ([@bib28]). At late Anagen/Catagen hypomethylation occurs and is maintained all through Catagen, to provide flexibility of fate acquisition for HFSCs subsequent fates. Blocking hypomethylation at late Anagen/Catagen results in persistence of the Anagen HFSC epigenetic state, a highly methylated rigid-SC state, which then limits HFSC genome plasticity in subsequent stages and results in transient defects in activation and differentiation.

Skin punch regeneration is another measure of HFSC plasticity, since they migrate upward and trans-differentiate to IFE ([@bib1], [@bib17], [@bib19], [@bib29], [@bib38]). We demonstrate by lineage tracing that hypomethylation is necessary for subsequent contribution of both HF (*Lgr5*-CreER) and IFE (*Aspm*-CreER) SCs to wound healing. We describe the *Aspm*-CreER as a newfound genetic tool to mark the IFE SCs specifically, away from the HF lineages. The *Aspm*-CreER mice have been previously generated ([@bib36]), but have not yet been studied in skin to our knowledge. Whereas HFSC contribution to epidermis repair has been intensively studied ([@bib1], [@bib17], [@bib19], [@bib29], [@bib38]), the contribution of epidermis to HFSCs upon injury has been more difficult, due to lack of specific and efficient genetic-labeling tools for the IFE. *De novo* HF regeneration from IFE SCs has been documented in severe injuries, such as very large skin excision or punch wounds ([@bib18], [@bib42]). With the *Aspm*-CreER-labeling tools, we demonstrate essentially no IFE cell migration to HF during normal homeostasis or in hair plucking, which then occurs specifically only near punch wound sites. It is possible that the IFE cells adopt new fates near the injury site, which may explain why H3 K27me3 mark is hypomethylated near wound edges ([@bib48]). More experiments are needed to understand if the IFE migrated cells actually contribute to HF growth, and whether methylation levels affect this process.

Interestingly, hypomethylation affected selectively epidermal cell differentiation and blood vessel recruitment in wound healing, but not epidermal cell proliferation and fibroblast recruitment. Our data suggest that a state of skin hypomethylation prior to injury may be beneficial to wound healing, as also suggested by low H3 K27me3 mark at the wound edge due to decreased PRC2 complex genes (*Ezh2* and *Eed*) and increased H3 K27me3 demethylases (*Utx* and *Jmjd3*) ([@bib48]). Hypomethylation of H3 K27me3 may be critical during wound healing, since injury-related genes, such as *Myc*, *Egfr* and *Mmp*s are de-repressed by loss of H3 K27me3 mark ([@bib41], [@bib48]). Moreover, depletion of *Jmjd3* fails to activate epidermal differentiation-related genes in human keratinocytes ([@bib47]). Previously, double knockout of *Ezh1/2* and loss of H3 K27me3 resulted in hyperproliferation in the BL of the epidermis in un-injured skin ([@bib9]). We have not observed a noticeable phenotype in the proliferation of the BL cells possibly due to compounding effects of H3 K7me3 with K4/9me3. This may point to complex interactions among various histone methyl marks that warrant further investigation.

Finally, despite global demethylase inhibition, we find that gene promoters are targeted differentially, with a selective upregulation of activating mark H3 K4me3 on the *Bmp4* promoter. BMP signaling may explain at least in part our phenotypes, given its known role in controlling SC quiescence, hair cycle progression, HF cell differentiation, and keratinocyte migration and differentiation in wound healing ([@bib5], [@bib21], [@bib23], [@bib30], [@bib44], [@bib50]). Interfering with BMP via NOGGIN injection rescued the hair cycle phenotype, adding to this model. Nevertheless, BMP is extremely unlikely the only pathway at play in the interface with histone methylation levels, and much more genomic work is required for a more comprehensive map of the pathways at play. BMP ligand expression is low at Anagen and increases at late Anagen/Catagen and throughout Telogen (this work) ([@bib6], [@bib26], [@bib43]). This BMP increase is accompanied by HFSCs hypomethylation along with decreased expression of histone methylases, such as *Setd1b* (H3 K4me3), *Suv39h2* (H3 K9me3), and *Ezh2* (H3 K27me3) ([@bib28]), decreased proliferative signals and HFSC quiescence ([@bib16], [@bib21], [@bib32], [@bib43]) ([Figure 6](#fig6){ref-type="fig"}A). Importantly, hypomethylation of H3 K4me3 was the mildest among the three different marks that decrease at Catagen ([@bib28]), with significant levels retained on the *Bmp4* promoter (this work). Although our previous data suggested that BMP may be upstream promoting hypomethylation ([@bib28]), we find here what may be a negative feedback loop in which hypomethylation may dampen the level of BMP4, primarily through maintaining H3 K4me3 levels ([Figure 6](#fig6){ref-type="fig"}L). We propose a working model for further investigation, in which a two-way dynamic feedback occurs between H3 K4/9/27 trimethylation and BMP signaling during different stages of the hair cycle ([Figure 6](#fig6){ref-type="fig"}L).

Altogether, our data using chemical inhibition of demethylases in skin provides a broad picture of how overall global histone H3 K4/9/27me3 levels can affect hair homeostasis and skin injury repair for future genetic testing and clinical applications.

Experimental Procedures {#sec4}
=======================

Mice, Histone DI Administration and Noggin Injection {#sec4.1}
----------------------------------------------------

All mice were treated according to Cornell University Institutional Animal Care and Use Committee protocols. Both males and females were used for all of the experiments, and were sex matched for Control (CT) and experimental groups. For applying DIs, GSK J1 (no. 4593, Tocris) and JIB 04 (no. 4972, Tocris) were dissolved in dimethylsulfoxide at 100 mM and then diluted in 100% acetone to the final concentration of 500 μM. CD1 × FVB littermates back skin was shaved and 100 μL of inhibitors were topically applied on the shaved regions every 12 hr for indicated periods ([Figures 1](#fig1){ref-type="fig"}B and [5](#fig5){ref-type="fig"}C). Control mice received only dimethylsulfoxide in acetone. For Noggin-coated bead injection, we followed a method described previously ([@bib28]). In brief, small regions of the DI-treated mice back skin was carefully clipped to avoid injury. Recombinant mouse Noggin (5 μg mL^−1^, 1967-NG-025 R&D Systems) was incubated with FluoSpheres (Invitrogen) for 30 min at room temperature, and injected intradermally for 4 consecutive days in the same region. Control sides were injected PBS only.

Western Blot {#sec4.2}
------------

For protein detection, we used mouse back skin which was harvested, snap frozen in liquid nitrogen and grated in the mortar. For [Figures 6](#fig6){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A, DI was treated at PD32-35 for PD35 samples and PD32-39 for PD39 samples. For the rest of the samples, DI was treated at PD35-42. All of the samples were lysed in RIPA buffer (10 mM Tris-Cl \[pH 8.0\], 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, 1 mM PMSF). The protein was detected using antibodies-H3 (1:5,000, ab1791, Abcam), H3 K4me3 (1:5,000, no. 39159, Active Motif), H3 K9me3 (1:5,000, ab8898, Abcam), H3 K27me3 (1:5,000, no. 07--449, Millipore), β-actin (1:2,000, MAB1501MI, Millipore), and BMP4 (1:1,000, ab39973, Abcam). ImageJ (<http://imagej.nih.gov/ij/>) was used for quantification of the blot intensity.

Immunofluorescence Staining {#sec4.3}
---------------------------

The tissue immunofluorescence staining method has been described previously ([@bib28]). Antibodies of H3 K4me3 (1:1,000, no. 39159, Active Motif), H3 K9me3 (1:2,000, ab8898, Abcam), H3 K27me3 (1:2,000, no. 07-449, Millipore), CD34 (1:200, no. 553731, BD Biosciences), mouse α-K14 (1:100, ab7800, Abcam), Ki67 (1:500, ab15580, Abcam), AE13 (1:50, IQ292, ImmuQuest), BMP4 (1:200, ab39973, Abcam), K1 (1:200, PRB165P, Covance), K10 (1:100, PRB159P, Covance), CD31 (1:200, no. 550274, BD Biosciences), Tenascin (1:500, AB19013, Millipore), pSmad1 (S463/465), 5 (S463/465), 9 (S465/467) (1:100, 13820S Cell Signal), and Vimentin (1:1,000, a gift from Dr. Yan Lammerding, Cornell University) were used.

qRT-PCR and FACS {#sec4.4}
----------------

For FACS sorting of HFSCs and BL cells, the protocol has been described previously ([@bib28]). The epithelial cells were isolated from the back skin through trypsin digestion. The cell suspensions were labeled with anti-CD34-Biotin (1:50, no. 13-0341-85, eBioscience), α-Streptavidin-APC (1:100, no. 554067, BD Biosciences) and anti-α6-integrin-PE (1:40, CD49f, no. 555736, BD Biosciences) to isolate HFSCs (CD34+, α6-integrin+) and BL cells (CD34−, α6-integrin+). Propidium iodide (1:1,250--1:2,500 of 1 mg mL^−1^ stock, S7109, Sigma) was used to rule out the dead cells. For negative controls to gate the fluorescence-labeled cells, we used only α-Streptavidin-APC for CD34+ cells and PE-Rat-IgG2a (1:40, no. 555844, BD Biosciences) for α6-integrin+ cells. The cells were isolated with BD FACSAria located in the Flow Cytometry Core at Cornell University.

For gene expression analysis, RNA was extracted from either 1 cm^2^ of total skin using the RNeasy Fibrous Tissue Mini Kit (no. 74704, QIAGEN) or the FACS-sorted cells using the mirVana miRNA Isolation Kit (AM1591, Ambion). The cDNA were synthesized using iScript (no. 1708841, Bio-Rad) cDNA synthesis kit and qRT-PCR analysis was described previously ([@bib28]).

ChIP {#sec4.5}
----

For ChIP analysis, we used 1 cm^2^ of CT- and DI-treated mice total skin as described previously ([@bib28]). DI was applied from PD32-35 for Anagen PD35 samples and PD32-39 for Catagen PD39 samples. Two micrograms of each H3 (ab1791, Abcam), H3 K4me3 (no. 39159, Active Motif), H3 K9me3 (ab8898, Abcam), H3 K27me3 (no. 07-449, Millipore), and IgG (ab18413, Abcam) were used for immunoprecipitation. Purified DNA samples were analyzed by qRT-PCR with *Bmp4* and *Wnt4* promoter targeting primers. The primers are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

Hair Plucking Experiments {#sec4.6}
-------------------------

For hair plucking, a hair removal sugar wax kit (Emerita) was used. *Aspm*-CreER;Rosa26 tdTomato mice were injected with 10 μg μL^−1^ of TM (200 μg g^−1^ body) at PD49. Then they were anesthetized and back skin hair was gently shaved (to avoid injury and unwanted hair growth activation) at PD70. A warm hair removal wax was applied to right side of back skin with a paper strip, and removed after 30 s. The wounded tissues were harvested after 2 weeks and 1 month.

Punch Wound Biopsy, *Ex Vivo* Biopsy Culture and Lineage Tracing Experiments {#sec4.7}
----------------------------------------------------------------------------

For all wounds 4 mm of disposable biopsy punches (no. 33-34, Integra Miltex) were used. PD49 mice were shaved and their back skin punch wounded, as described ([@bib11]), then sacrificed at different time points.

For lineage tracing experiments, *Lgr5*-CreER;Rosa26 tdTomato (Jackson Laboratory) and *Aspm*-CreER;Rosa26 tdTomato transgenic mice ([@bib35], [@bib36]) were used. First, these mice were injected with 10 μg μL^−1^ of TM (200 μg g^−1^ body). Then, GSK J1 (no. 4593, Tocris) and JIB 04 (no. 4972, Tocris) dissolved vehicles were applied on the back skin for a week. The wounded tissues were harvested after 1, 3, and 5 weeks after the punch wound.

Microscopy {#sec4.8}
----------

For [Figures 1](#fig1){ref-type="fig"}H, [3](#fig3){ref-type="fig"}G, [4](#fig4){ref-type="fig"}C, and [S1](#mmc1){ref-type="supplementary-material"}F, tissue samples were analyzed by confocal microscopy (Zeiss LSM710) with Zen 2012 software. Projected z stack images are viewed from the basal surface with stitched tiled images.

Otherwise we used a widefield fluorescence light microscope (Nikon) equipped with a charge-coupled device 12-bit digital camera (Retiga EXi; QImaging). For [Figures 1](#fig1){ref-type="fig"}G, 1I, [3](#fig3){ref-type="fig"}E, [5](#fig5){ref-type="fig"}B, and [S1](#mmc1){ref-type="supplementary-material"}C--S1E, images were taken individually and stitched together as a whole image.

Statistical Analysis {#sec4.9}
--------------------

All values were shown as mean ± SD. At least 3 mice (n \> 100 cells) were taken from each group for significant test (e.g., Student\'s t test and ANOVA for [Figures 1](#fig1){ref-type="fig"}F and [3](#fig3){ref-type="fig"}D) where p \< 0.05 was considered significant. For [Figures 1](#fig1){ref-type="fig"}F and [3](#fig3){ref-type="fig"}D, ANOVA significant test was performed using JMP software.
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